Biodistribution and Dosimetry Evaluation of [124I]FIAU



Status:Completed
Conditions:Orthopedic
Therapuetic Areas:Orthopedics / Podiatry
Healthy:No
Age Range:18 - Any
Updated:5/27/2013
Start Date:December 2010
End Date:March 2013
Contact:Martin R Feeney, B.Sc.
Email:martin.feeney@covance.com
Phone:1-250-348-1020

Use our guide to learn which trials are right for you!

Biodistribution and Dosimetry of [124i]FIAU in Patients With Prosthetic Joint Infection of The Knee or Hip and Healthy Subjects Using PET-CT Scanning


This protocol will evaluate the biodistribution and dosimetry of [124I]FIAU in both healthy
volunteers and patients with prosthetic joint infections. This pilot study will also
investigate the safety and tolerability of [124I]FIAU.


The following are the main inclusion criteria for all subjects:

1. Males or females age > 18 years

2. Informed consent

3. Subjects with chronic medical conditions such as hypertension and diabetes should be
considered stable by the principal investigator

4. Women should be postmenopausal or surgically sterile

5. Able to return for all study assessments

In addition, the following main inclusion criteria apply for subjects with suspected
prosthetic joint infection:

1. Operative intervention planned in the 30 days following study enrollment

2. Prosthetic joint implant in site for more than 3 months prior to enrollment

The following are the main exclusion criteria for all subjects:

1. Unable to comply with study requirements

2. Indication in the opinion of the principal investigator for surgery within 48 hours
of presentation.

3. Receipt of any antibiotic therapy in the 2 weeks preceding imaging

4. Immunosuppression, e.g., human immunodeficiency virus (HIV) infection, s/p organ
transplantation, receipt of steroids for > 10 days at > 10 mg of prednisone
equivalent daily within the 90 days prior to enrollment

5. Requirement for any medication that predisposes to lactic acidosis (e.g., metformin,
iron, isoniazid and salicylates; see Appendix A)

6. Requirement for any medication that has potential mitochondrial toxicity, e.g.,
nucleoside analogues (zidovudine, didanosine, stavudine)

7. History of an inherited mitochondrial disorder (e.g., Leber's hereditary neuropathy,
neuropathy, ataxia, retinitis pigmentosa and ptosis [NARP], myoneurogenic
gastrointestinal encephalopathy [MNGIE], myoclonic epilepsy with ragged red fibers
[MERFF] and mitochondrial myopathy, encephalomyopathy, lactic acidosis and
stroke-like syndrome [MELAS]

8. Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

9. Pre-existing myopathy or neuropathy

10. Abnormal liver function tests defined as alanine aminotransferase (ALT) > the upper
limit of normal (ULN), aspartate aminotransferase (AST) > ULN, gamma glutamyl
transferase (GGT) > ULN

11. Alcohol use > 3 units per day in men or 2 units per day in women or active
intravenous drug use

12. Creatinine clearance < 30 mL/min

13. Body mass index > 40

14. Life expectancy < 6 months

15. Hypersensitivity to iodine
We found this trial at
4
sites
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
(410) 601-9000
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
New Hyde Park, New York 11040
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials